TR200102403T2 - Piridopiranoazepin türevleri, bunların hazırlanmaları ve terapötik uygulamaları. - Google Patents

Piridopiranoazepin türevleri, bunların hazırlanmaları ve terapötik uygulamaları.

Info

Publication number
TR200102403T2
TR200102403T2 TR2001/02403T TR200102403T TR200102403T2 TR 200102403 T2 TR200102403 T2 TR 200102403T2 TR 2001/02403 T TR2001/02403 T TR 2001/02403T TR 200102403 T TR200102403 T TR 200102403T TR 200102403 T2 TR200102403 T2 TR 200102403T2
Authority
TR
Turkey
Prior art keywords
alkyl
group
hydrogen
preparation
therapeutic applications
Prior art date
Application number
TR2001/02403T
Other languages
English (en)
Inventor
Galli Frederic
Jegham Samir
Lochead Alistair
Samson Axelle
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of TR200102403T2 publication Critical patent/TR200102403T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Genel formül (I)'deki bilesikler olup, söz konusu formül içerisindeki, R1, bir hidrojen atomu, bir alkil, fenialkil, fenilhidroksialkil, furanilalkil veya furanilhidroksialkil gurubudur, R2; bir hidrojen veya halojen atomu veya bir triflorometil, siyano hidroksil, nitro, asetil, alkil, alkoksi veya içerisinde, R4 ve R5'in, her birinin bir hidrojen atomu veya bir alkil grubu oldugu veya bunlari tasiyan nitrojen atomu ile birlikte, bir C4-C7 halkasini olusturdugu, NR4R5 genel formülüne sahip bir amino grubu veya bir halojen atomu veya bir triflorometil, triflorometoksi, siyano, hidroksil, nitro, asetil, alkil, alkoksi veya metilendioksi grubu ile istege bagli olarak substitüsyonlu bir fenil veya naftil grubudur ve R3; bir hidrojen veya halojen atomu veya bir alkil grubudur.
TR2001/02403T 1999-03-05 2000-03-01 Piridopiranoazepin türevleri, bunların hazırlanmaları ve terapötik uygulamaları. TR200102403T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902784A FR2790474B1 (fr) 1999-03-05 1999-03-05 Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
TR200102403T2 true TR200102403T2 (tr) 2001-12-21

Family

ID=9542888

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02403T TR200102403T2 (tr) 1999-03-05 2000-03-01 Piridopiranoazepin türevleri, bunların hazırlanmaları ve terapötik uygulamaları.

Country Status (37)

Country Link
US (2) US6538003B1 (tr)
EP (1) EP1161434B1 (tr)
JP (1) JP4806123B2 (tr)
KR (2) KR20070086359A (tr)
CN (1) CN1137894C (tr)
AR (1) AR022820A1 (tr)
AT (1) ATE231869T1 (tr)
AU (1) AU764625B2 (tr)
BG (1) BG65211B1 (tr)
BR (1) BR0008763A (tr)
CA (1) CA2372063C (tr)
CO (1) CO5160250A1 (tr)
CZ (1) CZ302259B6 (tr)
DE (1) DE60001307T2 (tr)
DK (1) DK1161434T3 (tr)
EE (1) EE04497B1 (tr)
ES (1) ES2191611T3 (tr)
FR (1) FR2790474B1 (tr)
HK (1) HK1040398B (tr)
HR (1) HRP20010655B1 (tr)
HU (1) HU228671B1 (tr)
ID (1) ID30116A (tr)
IL (2) IL145150A0 (tr)
MX (1) MXPA01008972A (tr)
NO (1) NO327119B1 (tr)
NZ (1) NZ513561A (tr)
PE (1) PE20001543A1 (tr)
PL (1) PL201683B1 (tr)
RS (1) RS49997B (tr)
RU (1) RU2238273C2 (tr)
SK (1) SK284339B6 (tr)
TR (1) TR200102403T2 (tr)
TW (1) TWI222975B (tr)
UA (1) UA61164C2 (tr)
UY (1) UY26048A1 (tr)
WO (1) WO2000053608A1 (tr)
ZA (1) ZA200106811B (tr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CN100518823C (zh) 2002-07-18 2009-07-29 赛托斯生物技术公司 半抗原-载体偶联物及其用途
CN1735414A (zh) * 2002-12-06 2006-02-15 北岸长岛犹太人研究学院 用α7受体结合类胆碱激动剂抑制炎症
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
US20090076059A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dianicline
EP2623504A1 (de) 2007-12-07 2013-08-07 Abbott GmbH & Co. KG 5,6-Disubstituierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
WO2009071687A1 (de) 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg Amidomethyl-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
CA2707669C (en) * 2007-12-07 2016-07-05 Wilfried Braje 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
US8703774B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US9463190B2 (en) 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
ES2541528T3 (es) 2008-11-19 2015-07-21 Forum Pharmaceuticals Inc. Tratamiento de trastornos cognitivos con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
WO2010132423A1 (en) * 2009-05-11 2010-11-18 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
WO2010138600A2 (en) * 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
JP5749797B2 (ja) 2010-05-17 2015-07-15 フォルム ファーマシューティカルズ、インコーポレイテッド （ｒ）−７−クロロ−ｎ−（キヌクリジン−３−イル）ベンゾ［ｂ］チオフェン−２−カルボキサミド塩酸塩一水和物の結晶形
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
GB9301660D0 (en) * 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
JPH11512443A (ja) * 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物
FR2761072B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique
NZ500643A (en) * 1997-05-30 2001-12-21 Neurosearch As Spiro-quinuclidine derivatives and their use in treating conditions responsive to nicotinic ACh receptor modulators
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
WO2000053608A1 (fr) 2000-09-14
EE200100470A (et) 2002-12-16
EP1161434B1 (fr) 2003-01-29
PL201683B1 (pl) 2009-04-30
FR2790474A1 (fr) 2000-09-08
AU2922600A (en) 2000-09-28
BG65211B1 (bg) 2007-07-31
US20030187012A1 (en) 2003-10-02
PL352330A1 (en) 2003-08-11
CA2372063A1 (en) 2000-09-14
HK1040398B (zh) 2003-07-18
ZA200106811B (en) 2002-08-19
MXPA01008972A (es) 2002-03-27
KR20070086359A (ko) 2007-08-27
IL145150A (en) 2007-06-03
SK12422001A3 (sk) 2002-04-04
US6908927B2 (en) 2005-06-21
RS49997B (sr) 2008-09-29
KR100768355B1 (ko) 2007-10-17
EE04497B1 (et) 2005-06-15
EP1161434A1 (fr) 2001-12-12
BR0008763A (pt) 2002-01-02
AU764625B2 (en) 2003-08-28
HK1040398A1 (en) 2002-06-07
YU59601A (sh) 2004-03-12
ID30116A (id) 2001-11-08
JP2002539129A (ja) 2002-11-19
CN1137894C (zh) 2004-02-11
DE60001307T2 (de) 2003-12-11
UY26048A1 (es) 2000-09-29
US6538003B1 (en) 2003-03-25
IL145150A0 (en) 2002-06-30
HUP0201753A2 (en) 2002-09-28
CZ302259B6 (cs) 2011-01-19
ATE231869T1 (de) 2003-02-15
SK284339B6 (sk) 2005-02-04
HU228671B1 (en) 2013-05-28
TWI222975B (en) 2004-11-01
NO20014270L (no) 2001-11-05
DE60001307D1 (de) 2003-03-06
BG105828A (bg) 2002-03-29
NZ513561A (en) 2003-06-30
KR20010102492A (ko) 2001-11-15
HRP20010655A2 (en) 2002-08-31
HUP0201753A3 (en) 2004-12-28
JP4806123B2 (ja) 2011-11-02
CA2372063C (en) 2011-01-11
RU2238273C2 (ru) 2004-10-20
PE20001543A1 (es) 2001-03-18
FR2790474B1 (fr) 2001-04-06
CN1343208A (zh) 2002-04-03
AR022820A1 (es) 2002-09-04
CO5160250A1 (es) 2002-05-30
HRP20010655B1 (en) 2003-06-30
NO327119B1 (no) 2009-04-27
CZ20013102A3 (cs) 2002-01-16
NO20014270D0 (no) 2001-09-03
DK1161434T3 (da) 2003-05-26
ES2191611T3 (es) 2003-09-16
UA61164C2 (uk) 2003-11-17

Similar Documents

Publication Publication Date Title
TR200102403T2 (tr) Piridopiranoazepin türevleri, bunların hazırlanmaları ve terapötik uygulamaları.
AU2003273475A8 (en) N-(phenyl(piperidin-2-yl)methyl)benzamide derivatives, preparation thereof, and use thereof in therapy
AU2886395A (en) 2-{1',2',4'-triazol-3'-yloxymethylene}-anilides and their use as pest-control agents
TR200002953T2 (tr) İki halkalı hidroksamik asit türevleri
CL2004001109A1 (es) Compuestos tien-3-il-sulfonilamino(tio) carbonil-triazolin(tio)onas sustituidas; procedimiento de obtencion; compuestos intermediarios; uso de los compuestos; y agentes herbicidas.
TR200402577T4 (tr) Urasil bileşikleri ve bunların kullanımları
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
ATE179698T1 (de) Pyrrolidin- und oxazolidin derivate , ihre herstellung und ihre verwendung als thrombocyten- aggregations-hemmer
AR028648A1 (es) Derivados de 1,4-diazabiciclo[3.2.2]nonano-fenilisoxazol, su preparacion y su aplicacion en terapéutica
IT1232252B (it) Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
DE59108419D1 (de) Dicarbonsäureimide, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide
AR028647A1 (es) Derivados de 1,4-diazabiciclo[3.2.2]nonano benzoxazol, benzotiazol y bencimidazol, su preparacion y su aplicacion en terapéutica
DK1001937T3 (da) Fremgangsmåde til fremstilling af 2-(3-pyrazolyloxymethylen)nitrobenzener
FI964463A0 (fi) Bisykliset amidiinijohdannaiset typpioksidinsyntetaasin inhibiittoreina
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
HRP20040230B1 (hr) Agonisti muskarina
NO995289D0 (no) Benzimidazol-derivater
TR200000057T2 (tr) 6-pirolidin-2-ilpirindinler, hazırlanmaları ve terapötik uygulamaları.
TR199902115T2 (tr) 2,3- Dihidrofuro (3,2-b) piridiun türevleri, hazirlanislari ve terapide uygulanmalari.
CO5210860A1 (es) Nuevos derivados de pirimidina-2,4,6-triona
DE69914803D1 (de) Benzoxazol-derivate zur verwendung als integrin-inhibitoren
CO5090902A1 (es) Pirroles sustituidos
BR0114825A (pt) Pigmentos de monoazoquinolona, processo para sua preparação e seu uso
CO4940461A1 (es) Compuestos farmaceuticos piridinilpirimidinaminas
TR199801683A2 (tr) Yeni üre türevleri.